Metagenomi, INC Form 4 insider transactions

Laurence Reid, a Director at Metagenomi Therapeutics, Inc., has acquired stock options, indicating a potential long-term commitment and alignment with the company's future performance.

Metagenomi Therapeutics, Inc. reports that Director Willard H. Dere acquired 21,000 stock options.

Metagenomi Therapeutics, Inc. director Eric Bjerkholt acquired 21,000 stock options with an exercise price of $1.23.

Metagenomi Therapeutics, Inc. reports that Director Juergen Eckhardt acquired 21,000 stock options with an exercise price of $1.23.

Metagenomi Therapeutics, Inc. reports that Chief Financial Officer Pamela Wapnick sold 2,884 shares of common stock on June 5, 2026, to cover tax withholding obligations upon the vesting of restricted stock units.

Metagenomi Therapeutics, Inc. reports on stock transactions involving CEO Jian Irish, including automatic sales for tax withholding and shares held in trusts.

Metagenomi Therapeutics, Inc. reports that General Counsel Matthew Wein sold shares to cover tax obligations upon vesting of restricted stock units, not as a volitional trade.

Jian Irish, CEO and Director of Metagenomi Therapeutics, Inc., reported transactions involving restricted stock units and stock options.

Matthew Wein, General Counsel of Metagenomi Therapeutics, reported transactions involving restricted stock units and stock options.

Metagenomi Therapeutics reports on equity transactions involving Chief Financial Officer Pamela Wapnick, including restricted stock units and stock options.

Metagenomi Director Brian C. Thomas sold 3,830 shares of common stock to cover tax withholding obligations related to RSU vesting.

Metagenomi's General Counsel, Matthew Wein, sold 199 shares of common stock to cover tax withholding obligations related to RSU vesting.

Metagenomi's Chief Financial Officer, Pamela Wapnick, sold 1,576 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Metagenomi's CEO, Jian Irish, sold 1,602 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Metagenomi Director Brian C. Thomas executed a pre-planned sale of 2,701 common shares at $1.81 to satisfy tax withholding obligations from vested restricted stock units.

Metagenomi's Chief Financial Officer, Pamela Wapnick, reported the acquisition of 120,000 restricted stock units and a tax-related sale of 1,576 common shares.

Metagenomi CEO Jian Irish reported significant equity acquisitions, including restricted stock units and stock options, alongside a tax-related share sale.

Metagenomi General Counsel Matthew Wein reported recent stock transactions, including a tax-related sale, ESPP acquisitions, and a significant RSU grant.

Metagenomi, Inc. Director Laurence Reid was granted 42,000 stock options with an exercise price of $1.82, vesting over approximately three years.

Metagenomi, Inc. Director Juergen Eckhardt was granted 21,000 stock options with an exercise price of $1.57, vesting based on continued service.

Metagenomi, Inc. Director Willard H. Dere has acquired 21,000 stock options with an exercise price of $1.57, set to vest based on service conditions.

Metagenomi, Inc. Director Eric Bjerkholt was granted 8,572 stock options with an exercise price of $1.57, aligning his interests with the company's long-term performance.

Matthew Wein, Senior Vice President at Metagenomi, Inc., sold 199 shares of common stock for $1.75 per share to cover tax withholding obligations related to vested restricted stock units.

Metagenomi's Chief Medical Officer, Sarah B. Noonberg, sold 5,239 shares of common stock at $1.75 per share on June 6, 2025, to satisfy tax withholding obligations upon the vesting of restricted stock units.

Metagenomi, Inc.'s Chief Financial Officer, Pamela Wapnick, reported the sale of 1,576 shares of common stock at $1.75 per share to cover tax withholding obligations from the vesting of restricted stock units.

Metagenomi, Inc.'s CEO, Brian C. Thomas, reported an automatic sale of 10,785 common shares at $1.75 per share to satisfy tax withholding obligations related to the vesting of restricted stock units.

Metagenomi, Inc.'s President and Chief Operating Officer, Jian Irish, sold 6,390 shares of common stock at $1.75 per share on June 6, 2025, solely to satisfy tax withholding obligations related to restricted stock unit vesting.

Pamela Wapnick, CFO of Metagenomi, Inc., reports the acquisition of stock options and restricted stock units (RSUs) in the company.

Metagenomi's CEO, Brian C. Thomas, reports acquisition of 32,000 shares of common stock and 196,000 stock options.

Jian Irish, President and COO of Metagenomi, reports acquisition of restricted stock units and stock options, along with indirect holdings through trusts.